Mal-va-mac-SN38
Based on 1 Customer Validation
Mal-va-mac-SN38 is a drug-linker conjugate for ADC. Mal-va-mac-SN38 contains a ADC cytotoxin SN-38 (HY-13704) and a linker (HY-126364). Mal-va-mac-SN38 can rapidly and covalently bind with endogenous albumin in vivo, resulting in the formation of HSA-va-mac-SN38. Mal-va-mac-SN38 demonstrates exceptional stability in human plasma, and has anti-tumor and anti-metastasis effect.
For research use only. We do not sell to patients.
- Purity : 97.87%
- CAS No.: 2778229-31-3
- Formula: C52H61N7O14S
- Molecular Weight:1040.14
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Drug-Linker Conjugates for ADC Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 2778229-31-3
-
Appearance Solid
-
Molecular Weight 1040.14
-
Formula C52H61N7O14S
-
Color Light yellow to yellow
-
SMILES
O=C(N(COC1=CC=C(N=C(C(N2C3)=CC([C@@](O)(CC)C(OC4)=O)=C4C2=O)C3=C5CC)C5=C1)CCS(=O)(C)=O)OCC6=CC=C(NC([C@@H](NC([C@H](C(C)C)NC(CCCCCN7C(C=CC7=O)=O)=O)=O)C)=O)C=C6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (96.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9614 mL | 4.8070 mL | 9.6141 mL | 24.0352 mL |
| 5 mM | 0.1923 mL | 0.9614 mL | 1.9228 mL | 4.8070 mL | |
| 10 mM | 0.0961 mL | 0.4807 mL | 0.9614 mL | 2.4035 mL | |
| 15 mM | 0.0641 mL | 0.3205 mL | 0.6409 mL | 1.6023 mL | |
| 20 mM | 0.0481 mL | 0.2404 mL | 0.4807 mL | 1.2018 mL | |
| 25 mM | 0.0385 mL | 0.1923 mL | 0.3846 mL | 0.9614 mL | |
| 30 mM | 0.0320 mL | 0.1602 mL | 0.3205 mL | 0.8012 mL | |
| 40 mM | 0.0240 mL | 0.1202 mL | 0.2404 mL | 0.6009 mL | |
| 50 mM | 0.0192 mL | 0.0961 mL | 0.1923 mL | 0.4807 mL | |
| 60 mM | 0.0160 mL | 0.0801 mL | 0.1602 mL | 0.4006 mL | |
| 80 mM | 0.0120 mL | 0.0601 mL | 0.1202 mL | 0.3004 mL |
Mal-va-mac-SN38 Related Classifications
HY-159563 Related Classifications
Powered by Bioz